Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)
Luis E. Raez(Florida International University), Misako Nagasaka(University of California, Irvine), Hossein Borghaei(Fox Chase Cancer Center), Hirva Mamdani(Wayne State University), Daniel Sumarriva(Caris Life Sciences (United States)), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Mark A. Socinski(Florida Hospital Cancer Institute), Antoinette J. Wozniak(Wayne State University), Hina Khan(Brown University), Carlos Carracedo Uribe(Memorial Healthcare System), Gilberto Lopes(University of Miami), Jennifer R. Ribeiro(Women & Infants Hospital of Rhode Island)
Cited by 1
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k